Showing results (131-140 of 158) with videos related to
Sort By:
Pageof 16
Pulmonary Therapy|November 17, 2020
Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT TrialDavid M G Halpin, Gerard J Criner, Mark T Dransfield, et al.Chest|October 8, 2020
Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment TrialNicola A Hanania, David M Mannino, Gerard J Criner, et al.Annals of the American Thoracic Society|October 27, 2020
Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACTMark T Dransfield, Courtney Crim, Gerard J Criner, et al.International Journal of Health Policy and Management|August 6, 2025
Civil Society's Evidence-Generating Role for Health Policy Decisions: A Thematic Analysis of a Healthcare Information for All (HIFA) Community Online DiscussionUnni Gopinathan, Tarry Asoka, María Eugenia Aponte-Rueda, et al.JNCI Cancer Spectrum|July 25, 2020
Relationship of Cisplatin-Related Adverse Health Outcomes With Disability and Unemployment Among Testicular Cancer SurvivorsSarah L Kerns, Chunkit Fung, Sophie D Fossa, et al.Journal of Asthma and Allergy|October 31, 2024
Disease Burden and Access to Biologic Therapy in Patients with Severe Asthma, 2017-2022: An Analysis of the International Severe Asthma RegistryTham T Le, David B Price, Clement Erhard, et al.Plos Medicine|January 25, 2008
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastomaTim F Cloughesy, Koji Yoshimoto, Phioanh Nghiemphu, et al.Plos One|March 31, 2015
Elicitation of expert prior opinion: application to the MYPAN trial in childhood polyarteritis nodosaLisa V Hampson, John Whitehead, Despina Eleftheriou, et al.American Journal of Respiratory and Critical Care Medicine|March 13, 2020
Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary DiseaseDavid A Lipson, Courtney Crim, Gerard J Criner, et al.Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|November 6, 2020
InforMing the PAthway of COPD Treatment (IMPACT Trial) Single-Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: Analysis of the Western Europe and North America RegionsArnaud Bourdin, Gerard Criner, Gilles Devouassoux, et al.Pageof 16